Q4 Pharma Earnings Preview: J&J, Bristol And AbbVie
Johnson & Johnson has solid growth drivers in pharmaceuticals, but still faces an overhang related to talc controversy; Bristol's call will be dominated by the just-announced Celgene acquisition; and AbbVie will face questions about its cancer plans after expensive failure with Rova-T.
You may also be interested in...
Verona Investors Gasp As Lead Asset Misses Main Endpoint In COPD Trial
Verona’s shares sank after a brief three-day Phase II trial using lead asset RPL554 in patients already maximally bronchodilated on both a LAMA and LABA missed the primary endpoint.
AbbVie’s Business Development, Cancer Plans Not Put Off By Stemcentrx Disappointments
At J.P. Morgan, AbbVie said the clinical struggles of Rova-T won’t alter its deal-making plans and leave it with plenty of solid tumor possibilities. The pharma took a $4bn write-off of the Stemcentrx deal on Jan. 4.
Tizona Lands AbbVie Cancer R&D Deal As New CEO Takes Control
California-based Tizona has begun 2019 by installing a new CEO and winning a lucrative early-stage R&D pact with AbbVie aimed at commercializing cancer therapies targeting the immune system-suppressing enzyme CD39.